Use of aprotinin in pediatric lung transplantation

R. D B Jaquiss, C. B. Huddleston, T. L. Spray

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Aprotinin has been shown to decrease perioperative bleeding in adults undergoing cardiac surgery. We evaluated its efficacy in reducing blood loss in pediatric lung transplantation. Methods: Aprotinin was given to a group of pediatric lung transplant recipients (n = 24) identified as being at high risk for bleeding by virtue of preoperative diagnosis of cystic fibrosis or previous cardiothoracic operation (group 1). Comparison was made to a group of pediatric recipients (n = 19) believed to be at low risk for bleeding who did not receive aprotinin (group 2). All transplantations were accomplished with the use of cardiopulmonary bypass. Results: No difference in intraoperative blood requirement was identified between groups (18 ± 3 cc/kg [group 1] versus 30 ± 8 cc/kg [group 2], p = 0.16). Neither postoperative blood transfusion requirement (12 ± 5 cc/kg [group 1] versus 16 ± 6 cc/kg [group 2], p = 0.55) nor chest tube output in the first 24 postoperative hours (43 ± 9 cc/kg [group 1] versus 53 ± 13 cc/kg [group 2], p = 0.55) was significantly different between groups. Reexploration for bleeding was required in 8% (2 of 25) in group 1 and 16% (3 of 19) in group 2 (p = 0.64). Conclusions: Aprotinin reduced the amount of perioperative hemorrhage in a group of pediatric patients at high risk for bleeding after lung transplantation. The magnitude of the effect could not be quantified but was sufficient to normalize the transfusion requirement to that of a low risk group of patients.

Original languageEnglish (US)
Pages (from-to)302-307
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume14
Issue number2
StatePublished - Jan 1 1995

Fingerprint

Aprotinin
Lung Transplantation
Pediatrics
Hemorrhage
Chest Tubes
Cardiopulmonary Bypass
Cystic Fibrosis
Blood Transfusion
Thoracic Surgery
Transplantation
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Use of aprotinin in pediatric lung transplantation. / Jaquiss, R. D B; Huddleston, C. B.; Spray, T. L.

In: Journal of Heart and Lung Transplantation, Vol. 14, No. 2, 01.01.1995, p. 302-307.

Research output: Contribution to journalArticle

Jaquiss, RDB, Huddleston, CB & Spray, TL 1995, 'Use of aprotinin in pediatric lung transplantation', Journal of Heart and Lung Transplantation, vol. 14, no. 2, pp. 302-307.
Jaquiss, R. D B ; Huddleston, C. B. ; Spray, T. L. / Use of aprotinin in pediatric lung transplantation. In: Journal of Heart and Lung Transplantation. 1995 ; Vol. 14, No. 2. pp. 302-307.
@article{847520387bdd479e9129a686e533e775,
title = "Use of aprotinin in pediatric lung transplantation",
abstract = "Background: Aprotinin has been shown to decrease perioperative bleeding in adults undergoing cardiac surgery. We evaluated its efficacy in reducing blood loss in pediatric lung transplantation. Methods: Aprotinin was given to a group of pediatric lung transplant recipients (n = 24) identified as being at high risk for bleeding by virtue of preoperative diagnosis of cystic fibrosis or previous cardiothoracic operation (group 1). Comparison was made to a group of pediatric recipients (n = 19) believed to be at low risk for bleeding who did not receive aprotinin (group 2). All transplantations were accomplished with the use of cardiopulmonary bypass. Results: No difference in intraoperative blood requirement was identified between groups (18 ± 3 cc/kg [group 1] versus 30 ± 8 cc/kg [group 2], p = 0.16). Neither postoperative blood transfusion requirement (12 ± 5 cc/kg [group 1] versus 16 ± 6 cc/kg [group 2], p = 0.55) nor chest tube output in the first 24 postoperative hours (43 ± 9 cc/kg [group 1] versus 53 ± 13 cc/kg [group 2], p = 0.55) was significantly different between groups. Reexploration for bleeding was required in 8{\%} (2 of 25) in group 1 and 16{\%} (3 of 19) in group 2 (p = 0.64). Conclusions: Aprotinin reduced the amount of perioperative hemorrhage in a group of pediatric patients at high risk for bleeding after lung transplantation. The magnitude of the effect could not be quantified but was sufficient to normalize the transfusion requirement to that of a low risk group of patients.",
author = "Jaquiss, {R. D B} and Huddleston, {C. B.} and Spray, {T. L.}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "14",
pages = "302--307",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Use of aprotinin in pediatric lung transplantation

AU - Jaquiss, R. D B

AU - Huddleston, C. B.

AU - Spray, T. L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background: Aprotinin has been shown to decrease perioperative bleeding in adults undergoing cardiac surgery. We evaluated its efficacy in reducing blood loss in pediatric lung transplantation. Methods: Aprotinin was given to a group of pediatric lung transplant recipients (n = 24) identified as being at high risk for bleeding by virtue of preoperative diagnosis of cystic fibrosis or previous cardiothoracic operation (group 1). Comparison was made to a group of pediatric recipients (n = 19) believed to be at low risk for bleeding who did not receive aprotinin (group 2). All transplantations were accomplished with the use of cardiopulmonary bypass. Results: No difference in intraoperative blood requirement was identified between groups (18 ± 3 cc/kg [group 1] versus 30 ± 8 cc/kg [group 2], p = 0.16). Neither postoperative blood transfusion requirement (12 ± 5 cc/kg [group 1] versus 16 ± 6 cc/kg [group 2], p = 0.55) nor chest tube output in the first 24 postoperative hours (43 ± 9 cc/kg [group 1] versus 53 ± 13 cc/kg [group 2], p = 0.55) was significantly different between groups. Reexploration for bleeding was required in 8% (2 of 25) in group 1 and 16% (3 of 19) in group 2 (p = 0.64). Conclusions: Aprotinin reduced the amount of perioperative hemorrhage in a group of pediatric patients at high risk for bleeding after lung transplantation. The magnitude of the effect could not be quantified but was sufficient to normalize the transfusion requirement to that of a low risk group of patients.

AB - Background: Aprotinin has been shown to decrease perioperative bleeding in adults undergoing cardiac surgery. We evaluated its efficacy in reducing blood loss in pediatric lung transplantation. Methods: Aprotinin was given to a group of pediatric lung transplant recipients (n = 24) identified as being at high risk for bleeding by virtue of preoperative diagnosis of cystic fibrosis or previous cardiothoracic operation (group 1). Comparison was made to a group of pediatric recipients (n = 19) believed to be at low risk for bleeding who did not receive aprotinin (group 2). All transplantations were accomplished with the use of cardiopulmonary bypass. Results: No difference in intraoperative blood requirement was identified between groups (18 ± 3 cc/kg [group 1] versus 30 ± 8 cc/kg [group 2], p = 0.16). Neither postoperative blood transfusion requirement (12 ± 5 cc/kg [group 1] versus 16 ± 6 cc/kg [group 2], p = 0.55) nor chest tube output in the first 24 postoperative hours (43 ± 9 cc/kg [group 1] versus 53 ± 13 cc/kg [group 2], p = 0.55) was significantly different between groups. Reexploration for bleeding was required in 8% (2 of 25) in group 1 and 16% (3 of 19) in group 2 (p = 0.64). Conclusions: Aprotinin reduced the amount of perioperative hemorrhage in a group of pediatric patients at high risk for bleeding after lung transplantation. The magnitude of the effect could not be quantified but was sufficient to normalize the transfusion requirement to that of a low risk group of patients.

UR - http://www.scopus.com/inward/record.url?scp=0028948186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028948186&partnerID=8YFLogxK

M3 - Article

C2 - 7540042

AN - SCOPUS:0028948186

VL - 14

SP - 302

EP - 307

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 2

ER -